Synthetic Biology advances and applications in vaccine research

In R&D by Maria RelakiLeave a Comment

Sammy Farah - SGVI x90On the 12th April, the 3rd Day of the World Vaccine Congress Washington 2012, we had the pleasure to hear from Dr Sammy Farah, the President of Synthetic Genomics Vaccine Inc. (SGVI).

He joined the company in late 2011. He is an experienced vaccine executive, most recently coming from Immune Design Corp. where he was Chief Business Officer; and previous in his career, he was leader of manufacturing technical support for multiple commercial vaccine franchises at Merck & Co, Inc.

Dr Farah shared his views about the importnat work and research being undertaken at the SGVI and showed us examples of potential practical applications of synthetic functioning bacterial cells that mimicking M. Mycoides in vaccines. Could this be the new way forward in vaccine R&D?

It is one of the most significant breakthroughs in recent years and something that might have multiple applications in the near future.

Download Dr Farah's presentation from the Congress here.

Dr. Farah has also held roles in the business development and licensing group at Merck, executing external technology partnerships and research opportunities; and at Versant Ventures, as an investment professional specializing in biotechnology investing and new company formation. Dr. Farah received his MBA from the Wharton School, University of Pennsylvania, a Ph.D. in Biochemical Engineering from Stanford University and a B.S. in Biochemical Engineering from the Massachusetts Institute of Technology.

If you enjoyed the above, you might also be interested in:

- Advancements in Malaria vaccine production: Progress and challenges

- End #Polio now and how Disney & the Oscars played their role

Leave a Comment

Current ye@r *